HCPCS Level II · Drugs administered other than oral method
J2351Injection, ocrelizumab, 1 mg and hyaluronidase-ocsq
✓ Active
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About J2351
J2351 is an HCPCS Level II code in the J series (drugs administered other than oral method), describing injection, ocrelizumab, 1 mg and hyaluronidase-ocsq.
It was added to HCPCS effective 04/01/2025.
Its Medicare coverage code is "C", meaning coverage is left to the Medicare contractor's judgment.
Details
- Short description
- Inj ocrelizumab 1mg hya-ocsq
- Date added
- 04/01/2025
- Action effective
- 04/01/2025
- BETOS
- O1E
Related J23xx codes
- J2300Injection, nalbuphine hydrochloride, per 10 mg
- J2305Injection, nitroglycerin, 5 mg
- J2312Injection, naloxone hydrochloride, not otherwise specified, 0.01 mg
- J2313Injection, naloxone hydrochloride (zimhi), 0.01 mg
- J2315Injection, naltrexone, depot form, 1 mg
- J2320Injection, nandrolone decanoate, up to 50 mg
- J2323Injection, natalizumab, 1 mg
- J2325Injection, nesiritide, 0.1 mg
- J2326Injection, nusinersen, 0.1 mg
- J2327Injection, risankizumab-rzaa, intravenous, 1 mg
- J2329Injection, ublituximab-xiiy, 1mg
- J2350Injection, ocrelizumab, 1 mg
Common questions about J2351
Is HCPCS J2351 still valid?
- Yes. J2351 is active in the CMS October 2026 HCPCS file.
Does Medicare cover J2351?
- Its coverage code is "C": coverage is left to the Medicare contractor's judgment. Check the local coverage determination for your region.